Collaboration combines Repertoire's industry
leading DECODE™ platform that uniquely maps the immune synapse to
develop T cell targeted immune medicines with Bristol Myers
Squibb's world-leading expertise in developing and commercializing
innovative immune medicines
Repertoire will receive an upfront payment of
$65 million and is eligible to
receive up to $1.8 billion in
milestone and other payments and tiered royalties
CAMBRIDGE, Mass., April 29,
2024 /PRNewswire/ -- Repertoire® Immune
Medicines, a biotechnology company pioneering the discovery and
development of programmable T cell targeted immune medicines,
announced today that it has entered a multi-year strategic
collaboration with Bristol Myers Squibb (NYSE: BMY) to develop
tolerizing vaccines for up to three autoimmune diseases. The
collaboration aims to develop efficacious, selective, and durable
treatments for patients suffering from autoimmune disease by
resetting the immune system.
Under the terms of the agreement, Repertoire will receive an
upfront payment of $65 million, and
up to $1.8 billion for achieving
development, regulatory and commercial milestones in addition to
receiving tiered royalties.
Repertoire will lead all activities through to development
candidate nomination, while BMS will lead clinical development,
regulatory affairs, and commercialization of the tolerizing
vaccines under an exclusive world-wide license. Repertoire will
utilize its T cell receptor (TCR)-epitope discovery platform,
DECODE, and its proprietary lipid nanoparticle delivery technology
to discover and develop the tolerizing vaccine development
candidates. In addition, it will deploy DECODE to monitor immune
responses to the tolerizing vaccines in patients during clinical
development to provide key insights into the pharmacodynamic effect
of the vaccines.
"This agreement is a recognition of the transformative power of
Repertoire's DECODE platform to discover and develop programmable T
cell targeted immune medicines," said Torben Straight Nissen, Ph.D., CEO of Repertoire
and Executive Partner of Flagship Pioneering. "We are excited to
collaborate with Bristol Myers Squibb to combine their leadership
in immunology with our unique ability to discover key
disease-associated epitopes in patients with autoimmune diseases.
This collaboration enables us to serve patients suffering from
autoimmune diseases by translating our DECODE discoveries into
potentially transformative medicines that address the underlying
cause of their disease."
"Bristol Myers Squibb strives to change the treatment paradigm
for patients with autoimmune and immune-mediated diseases with a
commitment to the discovery and development of transformational
medicines," said Francisco Ramírez-Valle, M.D., Ph.D., senior vice
president and head of the Immunology & Cardiovascular Thematic
Research Center at Bristol Myers Squibb. "Our collaboration with
Repertoire aims to selectively reset the immune system, reflecting
a key component of our immunology research strategy, which we
believe may offer long term benefit while mitigating unintended
consequences associated with broad immune suppression."
About Repertoire® Immune Medicines
Repertoire Immune Medicines is a biotechnology company dedicated
to creating treatments for diseases based on the power of the human
T cell repertoire to eliminate cancer cells, target pathogens, and
regulate immune function in autoimmune disease.
The company's proprietary DECODE™ platform provides a
comprehensive understanding of the interactions between T cell
receptors and their antigens in disease. DECODE uniquely elucidates
the entire immune synapse, including the T-cell receptor-epitope
pairs that defines it, the HLA context, and the T cell phenotype.
This capability enables the creation of new and potentially
transformative classes of immune-based medicines. Repertoire
believes the ability to decipher these interactions represents one
of the greatest opportunities for innovation in medical science.
The company is utilizing the discoveries from DECODE to design and
develop novel immune therapies for multiple therapeutic areas, such
as autoimmune diseases, infectious diseases, and cancer.
Repertoire was founded in 2019 by Flagship Pioneering. Its team
operates from sites in Cambridge,
Massachusetts and Zurich.
To learn more about Repertoire, please visit our website:
www.repertoire.com and follow us on LinkedIn and Twitter.
Media Contacts
press@flagshippioneering.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/repertoire-immune-medicines-and-bristol-myers-squibb-announce-multi-year-strategic-collaboration-to-develop-tolerizing-vaccines-for-autoimmune-diseases-302127861.html
SOURCE Repertoire Immune Medicines